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Letters to the Editor
Nalidixic Acid-Resistant Strains of Salmonella Showing Decreased Susceptibility
to Fluoroquinolones in the Midwestern Region of the Republic of
Ireland Due to Mutations in the gyrA Gene
Salmonellosis is a significant public health problem world-
wide. It has been implicated in a number of food-borne out-
breaks in the Republic of Ireland; its prevention, surveillance,
and control have become a public health priority. To date, over
2,000 serotypes of Salmonella have been identified (6). The
European Food Safety Authority (EFSA) has called for the
monitoring of both nalidixic acid and ciprofloxacin resistance
levels in this bacterium at both country- and European Union-
wide levels (4).
Salmonella infection is associated primarily with gastroen-
teritis. This infection poses a serious health risk to populations
in the community such as the elderly, the young, and the
immunocompromised, where hospitalization may be required.
In such cases, effective antimicrobial treatment is essential and
the fluoroquinolones are an important class of antibiotic in the
treatment of salmonellosis. Little published information on the
fluoroquinolone antimicrobial susceptibility of Salmonella in
the Republic of Ireland is available. Previous reports indicated
the potential emergence of fluoroquinolone resistance in Irish
Salmonella isolates (6, 7).
The CLSI ciprofloxacin resistance breakpoint stands at 4
mg/liter, a concentration that has been questioned in recent
years. Many commentators believe a revision of the ciprofloxa-
cin resistance breakpoint is needed, as treatment failures have
occurred with both nontyphoidal and typhoidal salmonellae,
where the ciprofloxacin MIC is much less than 4 mg/liter (1, 3,
12, 13, 14). A breakpoint of 0.125 mg/liter has been recom-
mended (1).
We now provide an update on the occurrence of reduced
susceptibility to nalidixic acid and the monitoring of suscepti-
bility to ciprofloxacin and other fluoroquinolones in Salmo-
nella isolates from humans and food animals in the midwestern
region of the Republic of Ireland between 2007 and 2010.
Our study examined a total of 143 Salmonella isolates from
human (n  16), pet food (n  30), and veterinary (n  97)
sources in the midwestern region of the Republic of Ireland.
The human isolates were from the Mid West Regional Hospi-
tal; the veterinary isolates were from the Regional Veterinary
Laboratory in Knockalisheen, County Limerick; and the pet
food isolates were isolated from pig ear pet food treats man-
ufactured and sold in the midwestern region.
In our laboratory, these Salmonella isolates were tested
against nalidixic acid (30 g). Any nalidixic acid-resistant iso-
lates were then tested against ciprofloxacin (5 g), ofloxacin (5
g), pefloxacin (5 g), norfloxacin (10 g), and enrofloxacin (5
g) (Oxoid, Hampshire, United Kingdom) in accordance with
the CLSI guidelines for antimicrobial disc susceptibility testing
(2). The ciprofloxacin MIC was then determined for nalidixic
acid-resistant/intermediate isolates using Etests (Biodisk,
Solna, Sweden) on Mueller-Hinton agar (Oxoid, Hampshire,
United Kingdom). The CLSI breakpoints for the quinolones
for Enterobacteriaceae are outlined in Table 1.
The gyrA PCR was performed using primers P1 and P2 as
described by Griggs et al., and sequencing of the products was
carried out (7). Accession numbers are listed in Table 2. Esch-
erichia coli ATCC 25922 was included on each test occasion,
and all results were within the recommended limits, indicating
the validity of our test procedures.
Nalidixic acid resistance was observed in 13.3% (19/143) of
the isolates, and intermediate resistance was observed in 2.8%
(4/143) of the Salmonella isolates; these isolates are listed in
Table 2. The ciprofloxacin MICs obtained in this experiment
showed reduced susceptibility, with the nalidixic acid-resistant
isolates showing ciprofloxacin MICs of 0.125 to 1 mg/liter. The
isolates with intermediate nalidixic acid resistance showed no
reduced susceptibility to ciprofloxacin, with MIC values of
0.008 to 0.015 mg/liter. The nalidixic acid-resistant isolates also
showed reduced susceptibility to the other fluoroquinolones in
the disk diffusion tests (Table 2). For example, in S. Typhimu-
rium nalidixic acid-susceptible strains, a 10-g norfloxacin disk
showed a zone diameter of 29 mm. In contrast, nalidixic acid-
resistant isolate S. Typhimurium DT1 SC53 showed a zone
diameter of 19 mm, suggesting reduced susceptibility to fluoro-
quinolones. Similar differences in zone diameter can also be
seen for the other Salmonella isolates tested in this study (Ta-
ble 2).
A report by Gorman and Adley included 195 S. enterica
subsp. enterica isolates from human, food, and veterinary
sources in the midwestern region between 2000 and 2003.
Nalidixic acid resistance was observed in 2.6% (5/195) of the
isolates (6). The 13.2% of nalidixic acid-resistant isolates in our
study represents a rise. This could be potentially due to the
spread of resistant strains and the overuse of antibiotics in
humans and previous usage in animals (9, 10, 11). No resis-
tance or reduced susceptibility to ciprofloxacin was detected in
any of the isolates in this study (6).
In a report by Kilmartin et al., isolates of S. Enteritidis PT1
from all over Ireland were tested for susceptibility to nalidixic
acid and ciprofloxacin. Twenty-two out of 50 isolates were
found to be nalidixic acid resistant. The ciprofloxacin MICs for
these isolates were 0.25 to 0.5 mg/liter (8).
Mutations within the quinolone resistance-determining re-
gion (QRDR) of gyrA are believed to be one of the main
mechanisms of quinolone resistance. gyrA is a subunit of the
DNA gyrase enzyme. DNA gyrase is essential to the DNA
replication process; quinolones act by inhibiting this process.
TABLE 1. Resistance to quinolones and equivalent MIC breakpoint
for ciprofloxacin according to CLSI standards
Resistancea
Zone size (mm)b CIP MIC
breakpointNAL CIP OFX PEF NOR ENR
R 13 15 12 NA 12 NA 4
I 14–18 16–20 13–15 NA 13–16 NA
S 19 21 16 NA 17 NA 1
a R, resistant (no zone diameter was observed); I, intermediate resistance; S,
susceptible.
b NAL, nalidixic acid; OFX, ofloxacin; PEF, pefloxacin; NOR, norfloxacin;
ENR, enrofloxacin; CIP, ciprofloxacin; NA not applicable.
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The nalidixic acid-resistant isolates all contained mutations in
the QRDR of gyrA. The four intermediately nalidixic acid-
resistant isolates had no mutations in the QRDR of gyrA. Five
nalidixic acid-resistant isolates contained a mutation of serine
83 (Ser-83) to phenylalanine, four contained a mutation of
Ser-83 to tyrosine, and another one contained a mutation of
Ser-83 to proline. Six nalidixic acid-resistant isolates were
found with the aspartic acid 87 (Asp-87)-to-tyrosine mutation,
two had Asp-87 mutated to asparagine, and one had Asp-87
mutated to valine (Table 2). These mutations have all been
reported previously. Giraud et al. suggested that a mutation at
codon 83 conferred a higher resistance to quinolones than
mutations at codon 87 (5). Results of our study mostly conform
to this hypothesis; the strains with mutations at codon 83 had
ciprofloxacin MICs of 0.25 to 1 mg/liter, except for the one
isolate; S. Typhimurium DT1 SC53, which had a ciprofloxacin
MIC of 0.125 mg/liter. All isolates that had mutations at codon
87 had a MIC of 0.125 mg/liter (Table 2). A similar sequence
analysis was also carried out by Kilmartin et al. on the gyrA
gene of their nalidixic acid-resistant isolates (8). They also
found that isolates that had reduced susceptibility to cipro-
floxacin had mutations at the same positions. Many similar
studies from other countries indicate that a reduction in sus-
ceptibility to ciprofloxacin is linked with mutations of the gyrA
gene (9, 11).
This antimicrobial susceptibility report highlights the need
for continuous monitoring of fluoroquinolone usage in animal
and human medicine and for surveillance of antimicrobial re-
sistance of Salmonella in accordance with the call of the EFSA.
REFERENCES
1. Aarestrup, F. M., C. Wiuff, K. Molbak, and E. J. Threlfall. 2003. Is it time to
change fluoroquinolone breakpoints for Salmonella spp.? Antimicrob.
Agents Chemother. 47:827–829.
2. Clinical and Laboratory Standards Institute. 2008. Performance standards
for antimicrobial susceptibility testing; eighteenth informational supplement;
CLSI document M100-S18. Clinical and Laboratory Standards Institute,
Wayne, PA.
3. Crump, J. A., T. J. Barrett, J. T. Nelson, and F. J. Angulo. 2003. Reevalu-
ating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi
and for non-Typhi salmonellae. Clin. Infect. Dis. 37:75–81.
4. European Food Safety Authority. 2010. Manual for reporting on zoonoses,
zoonotic agents and antimicrobial resistance in the framework of Directive
2003/99/EC and of some other pathogenic microbiological agents for infor-
mation derived from the reporting year 2009. EFSA J. 8:1579. http://www
.efsa.europa.eu/en/scdocs/doc/1579.pdf.
5. Giraud, E., A. Brisabois, J. L. Martel, and E. Chaslus-Dancla. 1999. Com-
parative studies of mutations in animal isolates and experimental in vitro-
and in vivo-selected mutants of Salmonella spp. suggest a counterselection of
highly fluoroquinolone-resistant strains in the field. Antimicrob. Agents Che-
mother. 43:2131–2137.
6. Gorman, R., and C. C. Adley. 2003. Nalidixic acid-resistant strains of Sal-
monella showing decreased susceptibility to fluoroquinolones in the mid-west
region of the Republic of Ireland. J. Antimicrob. Chemother. 51:1047–1049.
7. Griggs, D. J., K. Gensberg, and L. J. Piddock. 1996. Mutations in gyrA gene
of quinolone-resistant Salmonella serotypes isolated from humans and ani-
mals. Antimicrob. Agents Chemother. 40:1009–1013.
8. Kilmartin, D., D. Morris, C. O’Hare, G. Corbett-Feeney, and M. Cormican.
2005. Clonal expansion may account for high levels of quinolone resistance
in Salmonella enterica serovar Enteritidis. Appl. Environ. Microbiol. 71:
2587–2591.
9. Marimo´n, J. M., M. Gomariz, C. Zigorraga, G. Cilla, and E. Perez-Trallero.
2004. Increasing prevalence of quinolone resistance in human nontyphoid
Salmonella enterica isolates obtained in Spain from 1981 to 2003. Antimi-
crob. Agents Chemother. 48:3789–3793.
10. Matheson, N., et al. 2010. Ten years experience of Salmonella infections in
Cambridge, UK. J. Infect. 60:21–25.
11. Murray, A., J. E. Coia, H. Mather, and D. J. Brown. 2005. Ciprofloxacin
resistance in non-typhoidal Salmonella serotypes in Scotland, 1993-2003. J.
Antimicrob. Chemother. 56:110–114.
12. Parry, C. M., and E. J. Threlfall. 2008. Antimicrobial resistance in typhoidal
and nontyphoidal salmonellae. Curr. Opin. Infect. Dis. 21:531–538.
13. Parry, C. M., et al. 2010. Suitable disk antimicrobial susceptibility break-
points defining Salmonella enterica serovar Typhi isolates with reduced sus-
ceptibility to fluoroquinolones. Antimicrob. Agents Chemother. 54:5201–
5208.
14. Vasallo, F. J., et al. 1998. Failure of ciprofloxacin therapy for invasive
nontyphoidal salmonellosis. Clin. Infect. Dis. 26:535–536.
Michael P. Ryan
Colm Dillon
Catherine C. Adley*
Microbiology Laboratory
Department of Chemical and Environmental Sciences
University of Limerick
Limerick, Ireland
*Phone: 353 61 202646
Fax: 353 61 202568
E-mail: Catherine.Adley@ul.ie
 Published ahead of print on 9 March 2011.
VOL. 49, 2011 LETTERS TO THE EDITOR 2079
